NCT00594386 - An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease | Biotech Hunter

Enrollment

258

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Parkinson's Disease

Interventions

DRUG

Rotigotine

"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: Allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."

Trial Locations (41)

Unknown

Huntsville

Peoria

Phoenix

Tucson

Hot Springs

Fountain Valley

Fresno

Irvine

Los Angeles

Danbury

Fairfield

New Haven

Miami

Pompano Beach

St. Petersburg

Sunrise

Atlanta

Hoffman Estates

Fort Wayne

Kansas City

Lexington

Boston

Southfield

Minneapolis

Henderson

Albany

Forest Hills

Louisville

Asheville

Raleigh

Toledo

Upland

Houston

San Antonio

Richmond

Roanoke

Milwaukee

Edmonton

Ottawa

Montrél

Saskatoon